Veeva Vault CRM Gains Momentum with Top Pharma Companies Committing to Migration

Barclays reports that six of the top 20 pharma companies have committed to Veeva Vault CRM, while only two have committed to Salesforce Life Sciences Cloud. This is highlighted after Merck announced its commitment to migrate to Vault CRM. Barclays maintains an Overweight rating and $300 price target on Veeva shares.

Merck & Co., Inc. (MSD outside the United States and Canada), one of the world's leading pharmaceutical companies, has announced its commitment to adopting Veeva Vault CRM. This strategic move is set to support Merck's significant launch period across new therapeutic areas and modalities [1].

The adoption of Veeva Vault CRM follows a growing trend in the biopharma industry, with six of the top 20 global pharmaceutical companies now committed to migrating to the platform. This commitment includes Merck, which is the largest pharma company by revenue globally [2]. In contrast, only two of the top 20 companies have committed to Salesforce's Life Sciences Cloud [2].

Veeva Systems (VEEV) has seen rapid adoption and strong growth for its Vault CRM, with over 80 live deployments and 28 new customers added or migrated in the first quarter of 2026. This marks a substantial increase in adoption, driven by the platform's purpose-built life sciences functionality [2]. The platform's subscription revenues grew 19% year over year to $634.8 million, with Vault CRM contributing meaningfully to this growth [2].

Merck's decision to adopt Veeva Vault CRM is seen as a significant endorsement for the platform, given the company's long-term strategic partnership with Veeva. The partnership is expected to provide Merck with the technology foundation to drive commercial execution, supporting its expansion into new therapeutic areas and modalities [1].

In response to Merck's announcement, Barclays has assigned an 'Overweight' rating and a $300 price target to Veeva shares. The stock has seen significant gains, with a year-to-date increase of 35% and approximately 51% over the past 12 months [2].

References:
[1] https://www.contractpharma.com/breaking-news/merck-adopts-veeva-vault-crm/
[2] https://www.ainvest.com/news/veeva-systems-vault-crm-continues-gain-momentum-top-biopharma-adoptions-features-2507/